JHVEPhoto / Shutterstock.com
As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
The showdown between Amgen and Sanofi concerning the proper test for enablement under Section 112 of the US Patent Act has finally taken place at the US Supreme Court.
The patents at the heart of the high-profile dispute between the two pharma companies deal with a special class of drugs (monoclonal antibodies) and a special class of patent claims (functional or genus claims).
Yesterday, on March 27, the court examined the following question:
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Amgen, Sanofi, SCOTUS, enablement, patents, dispute, US Patent Act, US Court of Appeals for the Federal Circuit, certiorari, oral argument